Investing with a Dream
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because all the preliminary investigational efficacy studies were performed on humans, not otters.
In a previous post I wrote the following, "Compounding revenues will only grow if SCRC increases MAV's staff & facility or expands the number of pharmacies filling prescriptions". Then I read in Friday's PR that Mr. Schneiderman plans to acquire equity interest in two additional pharmacies. This is a brilliant strategy to protect a revenue stream which could feel the impact of insurance regulations affecting reimbursements. One thing I know for sure, compounding is here to stay. Physician will continue to write these scripts and patients like the benefits of this mode of therapy. This is a $5.6B market which is not monopolized by any one company. Let's say MAV's revenues realize a loss of 10-30% (just a guess), and SCRC averaged $4M each month. Monthly revenues would now be $2.8M - $3.6M, if SCRC acquires interest in two additional pharmacies generating the same volume, total monthly revenues could top $6M each month. Could you imagine the monthly revenue number if Mr. Schneiderman continues to add pharmacies?
We have to remember, MAV is not the revenue stream. Compounding pharmacy is. I see future PRs stating "SCRC's monthly revenues for compounding were $6M" versus "MAV reported x-amount of revenues".
Mr. Schneiderman also highlighted the importance of a diversified product line with "PIMD, the Diabetic Medical Supplies line, additional pharmacies, and, prospectively, a Physician dispensing program", all of which will impact profitability. We already saw the impact PIMD ($554K) and Diabetes ($103K) in this week's PRs. Notice too, he mentions additional pharmacies. In reference to what I wrote in the above paragraph, this guy knows what he's doing. I am excited to hear more about the physician dispensing program. Being in the pharma industry for over 37 years, I can tell you, this has enormous potential.
Do I like the decision from one insurance carrier to not reimburse – NO, absolutely not! Do I like what Mr. Schneiderman is doing to maintain and grow the revenue stream – YES, definitely! Plus, let’s not forget about RapiMeds. I know it’s a sore subject for some, but as long as Mr. Schneiderman believes RapiMeds will be a reality, so do I.
My bottom line - SCRC is stronger now as a company then ever before.
Cosmo reminded me I left something out. How could I forget to include the addition of Gregory FCA as a reputable IR firm brought on by Mr. Schneiderman. Come to think about it, how many penny stocks can afford to hire on such an influential IR firm? I seriously doubt Mr. Schneiderman would bring on Gregory FCA if he didn't believe SCRC had a impactful message to deliver to the investment community. It's all about timing and Mr. Schneiderman's knows what he is doing.
We can have a lot of fun with revenue projections, but what excites me most is ScripsAmerica now has three solid revenue streams. Number one is Compounding Pharmacy. Compound Pharmacy is not facing anything unusual right now. My 37 years in the industry allows me to say with confidence all pharma companies deal with the same deductible issue patients face at the beginning of the year. Compound Pharmacy will as strong as ever by March. The reason is because patients need and want this therapy and secondly physicians have more confidence in compounding than they do in oral medications. Next SCRC now has PIMD growing and producing revenues each month, the potential with PIMD will add significantly to the bottom line as we progress throughout the year. Third SCRC has the new diabetes patient supply program which I believe will grow significantly each month as well. Mr. Schneiderman has developed a business model which is flourishing. By the end of the year we won't recognize this company. How about RapiMeds? As far as I am concerned, as long as Mr. Schneiderman maintains his excitement and belief in this product, so will I. When RapiMeds joins the SCRC bottom line, I agree it will cause a "buying frenzy". Revenues, Bank Financing, Cash in the Bank, and a CEO who is driven to success, SCRC is solid and is in good hands.
Rocky, there are a lot of projections being posted for what February will bring in revenues. Too many factors impacting February revenues, but I will say SCRC will eventually achieve a $100M Annual Run Rate. It's going to happen!
Rocky, all of the performance indicators for ScripsAmerica are pointing North. There isn't one revenue stream performing in the negative. With money in the bank, funding from a reputable institution, several profitable revenue streams, and a new IR Team on board, SCRC and Mr. Schneiderman are proving the business model he created two years ago is real and is working. The future is very promising. Now I know there are still those who have doubts, and that's okay. I am confident their concerns will be resolved in the months to come. Yes, it's been a long two years, but it is all coming together now.
Rocky, I believe the potential with the diabetes revenue stream is unlimited. I remember when Scrips reported $375K in compound pharmacy a year ago. Now we have a monthly average near $5M. This is what will happen with the diabetes business. A year from now we won't recognize it. I see this 500 patients easily growing by 500+ a month. Keep in mind though, with all these types of pharmacy supply programs there is monthly attrition rate, but the monthly total number of register patients will grow like compound (no pun intended) interest. What are witnessing is Mr. Bob Schneiderman's business model coming to life in a big way. I've been around for two years now and not to brag, I have a sizable position. Although there are some who share varying opinions, my decision to support SCRC has never changed. SCRC is slowly building into a powerhouse. With Gregory FCA now on board now as SCRC's IR Team, the visibility and awareness we'll see created will drive SCRC's success beyond our greatest expectations. As I mentioned to another member of the CORE, every revenue stream trend line is pointing upward. We will soon break away from the .18's just like we did when we were in the .08-.09 range. No worries here, this stock is going to be historic.
Thanks Rocky. It great to hear you were able to communicate with GFCA. We all know your comments are accurate and fall right in line with what Celtics has stated over and over again. Back to back to "BACK" profitable quarters are what we need to show the investment world SCRC is a serious company on a mission. With everything going on, too much to mention again, all the trend lines are pointing NORTH! It sounds like GFCA is ready to move with it's initiative to grow SCRC awareness and number of investors. Like I said before SCRC has been served up on a silver platter. To me, it's a "NO BRAINER". The 10K will be a valuable marketing tool for GFCA to demonstrate SCRC' incredible success in 2014. The diabetes and PIMD announcements in 2015 demonstrates SCRC's mission to grow the business and increase profit margins. I've added 10K in the last couple weeks, I only wish it could be more.
Gregory FCA couldn't ask for a better client than SCRC. Everything is looking great. With the 2014 10K coming out mid March showing a profitable year, along with the diabetes growing revenue stream, PIMD, etc., they should have enough ammo to build one incredible promotional theme to their investor base. Nothing fabricated here, the results are real and very positive. GO SCRC!!!
On our conference call with Mr. Schneiderman, he stated he would sit on the DEA’s doorstep to get PIMD licensed in New Jersey. It must have worked. This is huge and will have an incredible impact on SCRC's bottom line each month.
PIMD International is currently DEA-licensed to receive, store and ship Schedule 3 through Schedule 5 formulary pharmaceuticals. The company is also state-licensed to distribute pharmaceuticals in Florida, New Jersey, New York, Texas, Pennsylvania, Tennessee, Arizona, Kentucky, Alabama, Illinois, and Ohio and will continue to apply for additional state licenses throughout the United States.
Congratulations Mr. Schneiderman!
Merry Christmas to everyone on IHub. Mr. Schneiderman gave us all a gift with today closing at .1575. And, things will only get better. Year end 2014 is setting the stage for 2015 to be explosive for SCRC.
It is really nice to see all of the positive activity on this board. Mr. Schneiderman set this all in motion according to his timing and his plan. For months we were all wondering when he would reach out to a larger investor's base. Well, it all started with the SeeThruEquity conference in New York where he was able to discuss SCRC with key investment groups. He then followed that up with an investors conference call at the beginning of this month. It was all about timing. He knew exactly when the best time was to begin his SCRC awareness program. On the conference he discussed several topics, one was the negotiations to complete a bank deal which resulted in securing a $4M line of credit. Next he discussed his goal of winning the PIMD licensing in New Jersey and the high level of urgency placed on accomplishing this. I believe in short order we will hear the results of efforts. Next he was very positive on being able to announcement completion of the RapiMeds launch in Hong Kong and the Asian markets in the very near future. He has demonstrated he keeps word and I can see these announcements coming out soon.
So let's talk about compounding. Q3 delivered incredible revenues which resulted in $1.2M cash in the bank. Based on October and November revenues I expect Q4 to be another huge success with a record breaking quarterly performance. Back to back Q3 and Q4 results are in my mind what investors are looking for to secure their confidence in SCRC as a solid long term investment. Is the confidence growing, you bet it is. Just look at the last two days with combined volume of close to 4M shares traded. I expect we will see fluctuation in the weeks to follow but the trend will be pointing North from this point on.
Over the past several months we have read comments from both sides of the fence. Honestly, even though I always tried to be positive there were times I didn't know what to think. But I never doubted Mr. Schneiderman's word to deliver results, and it is obvious right now he is making it happen. With cash in the bank, financing secured, the expanding success of compounding, NJ PIMD getting closer, and the imminent success of RapiMeds in the Asian market, the future for SCRC couldn't be brighter.
2015 is going to be explosive. GO SCRC!!!
So when is the funeral?
The misery is finally over. Accept your loses here and move on.
About two years ago, on the advice of a wise investor friend, I sold my 1.4M shares of HYII at .04. At the time it was a huge lose. Today, I see it as a huge victory. hardasset, you were right about this stock all along. There won't be any bouncing back after ten days because there is no company, never has been.
Yes CHP, I would be interested as well to see where in the SEC filings this breakdown of shares can be found. As Rocky requested, please cut and paste it for all of us to see. Or, simply post the link to the site for this information. Thanks.
Someday I hope I can be as knowledgeable about the stock market as you and CHP are. Your insights are truly amazing and leave every investor wondering how you guys could be so smart. Based on your posts I would assume you both are worth millions because you seem to know everything. Since SCRC is not worth investing in please send me a private message with the names of stocks where I can gain immediate success. I will sell my SCRC and invest in your top picks ASAP. Thanks.
Mr. Schneiderman always answers my calls and has responded to every email I've sent.
What other penny stock posts $4.09 in monthly revenues? The pps will take care of itself.
Rocky, What we'll have here is six straight months of record breaking revenues. My guess for July a 15% gain to $3.1M. That puts us at a $37M annual run rate. Is there another penny stock performing like this? Soon SCRC will be too expensive for the manipulators to continue to play in this arena. Let them have their fun now. With revenues like this, we all know the future looks pretty darn good.
Rocky, I will keep my eye on this one. Nice to see you here.
I agree Rocky, selling at this time makes absolutely no sense at all to me. But then again, everyone has their own investment goals. I can respect that. If an investor is not happy with what they see the best thing to do is sell and move on.
Thanks Rocky, very good article. Last Wednesday evening I attended a medical conference on treating chronic pain. When the speaker asked the physicians in attendance what steps they take before prescribing opioids/narcotics, one physician stated he uses compounding creams and has seen very good results. The fear of prescribing opioids along with the DEA regulations and monitoring has led to pain specialists resorting to other less addictive modes of therapy. I know several plastic surgeons who like compounding creams to prevent scarring, but the multi-billion dollar chronic pain market could provide a huge opportunity for the compounding pharmacy market. SCRC has positioned itself very nicely to capture a sizable portion of this market place. With six straight months of growth, it is apparent Mr. Schneiderman is doing something right. I would hope he is working on other opportunities to expand the growth potential in this market place. With five other revenue streams contributing to the bottom line, SCRC is gaining serious momentum in becoming a financial powerhouse. I look forward to the results in the months to follow.
You are right spencer, SCRC is nothing but a pyramid scheme. Yep, this pyramid scheme will report July revenues of around $3M yet another record breaking month. What's that, six months in a row of positive growth? Pyramid scheme - really? Longs now selling is a blatant lie, not from where I sit. Get your facts straight.
Looks like another SCRC record breaking revenue month is in store for July. For those not counting that is 6 months in a row. Today's mid month PR revenue report almost equals the total revenues for May. There can't be any argument, SCRC is on the move. Can it get more exciting than this? GO SCRC!!!
Rocky, all I know is what I read in PRs. But if additional States are part of Mr. Schneiderman's master plan, then one could easily double the figure I posted. Wait to buy? No way!
There are only two types of investors (short & long term) and SCRC can be a winner for each of them. But, for anyone who truly understands SCRC and has watched the revenues increasing each month, there is no reason to sell at this time. We have two more weeks to go in July and based on the past five record breaking months of performance I see Main Ave reporting revenues in the $3M rate, a $36 annual run rate. I don't think we'll see 50-60% increasing anymore. I'm not being negative at all. Based on my own DD conducted a few months ago, I reported a healthy compound pharmacy should report $4 - $4.5M in monthly revenues. SCRC will definitely get there over the several months. These are exciting times for SCRC and for it's investors.
I'm guessing the "cash flow positive" PR should come soon. Just my guess. Looking at the last five months of revenues, July revenues should be awesome.
Back by the growing revenues, the "Cash Flow Positive" PR will be the major catalyst to PPS acceleration. We are "half way there", if not closer.
My guess is July will be SCRC's best month ever. After all, there has been five straight months of revenue increases and the opportunity for continued growth over the months to follow still exists. Keep in mind though, with just one pharmacy, the compounding revenue percent growth will eventually stabilize but even at that time the other revenue streams such as PIMD and RapiMeds will be adding significantly to the bottom line. Mr. Schneiderman has developed a little powerhouse in SCRC. Being a long term investor for over a year and a half, I couldn't be more excited about what the future will bring for SCRC. For anyone looking at SCRC, do your own DD, and I am confident you'll agree .14 is an excellent entry price. Go SCRC!!!
CHP, I was referring to the negativity referring to SCRC as everything but a viable stock and name calling from months ago. I fully agree there are reasons to share a "neutral thesis" and I am, and always have been, very willing to read both perspectives from every investor. This type of dialogue is actually healthy. June revenues report is a statement that SCRC is moving forward in a positive manner. Its hard to argue that type of success.
Yep, $2.7M worth vs $1.6M in May. SCRC is moving forward with strong ORDERS and REVENUES.
It's just going to get better and better Harvey. Nothing is stopping SCRC now. I can't even believe anyone can still be negative. $2.7M in June revenues - THAT SAYS IT ALL!
I am speechless. I was guessing $2.1M June revenues, this news simply blows me away. We have a true winner here in SCRC. $32M annual run rate. A penny stock???
Rocky, it will be exciting to hear what Mr. Schneiderman has in store for us this month.
pipe, I am looking forward to another week of SCRC's climb to success. Hopefully we will learn the total revenues for June and the final Q2 results. GO SCRC!!!
Rocky, SCRC is ready to launch. We've waited long enough. We all talked about patience and our time has arrived.
June Compounding Pharmacy revenues anywhere near $2M will be a huge boost to the Q2 final numbers.
You are right martin. The revenues being generated are for real. I can't see how anyone can argue the results. Believe in Bob and SCRC, why not? SCRC is developing momentum each and every month. I can't wait to hear the final June and Q2 numbers. From near $0 revenues in January to $4.5 M in six months. Show me another penny stock with that kind of growth. Reading this board can be a challenge to new investors. I say look at the results. As one poster commented, "SCRC is half way there". That statement alone speaks volumes. All the revenue streams are progressing nicely. SCRC will be the success we all knew it would become.
Panther, I am glad you brought up that iron ore experience. What a huge contrast looking at the two penny stocks. One had absolutely nothing going on, no production, no revenues, nothing. Now we have SCRC. With SCRC there exists products and services, real time revenues increasing on a monthly basis, and potential for growth in a diversified business model. I stated a few weeks ago, based on the previous quarters performance, that SCRC would post $2.1M in compounding pharmacy revenues for June. I still believe we will come in pretty close to that number giving us a Q2 total revenue final around $4.5M. No bad for a penny stock. Q2's performance should help us launch out of this .12 to .13 range. How much, anyone's guess. The next big catalyst which should be announced soon would be "cash flow positive". With these revenues I would expect that announcement anytime in the near future.
One thing about the compounding pharmacy revenues. We have seen an explosion of activity in the last five quarters. As the revenue volume continues to grow, I would not expect the 35-60% increases like we've seen. I would guess from this point on a 10% increase in revenues each month. This is true for all companies, as the volume increases the percent increase declines but the volume generated is still very significant.
SCRC is in great shape. I waited this long and I will continue to wait because right now this little stock is tracking at a run rate of $20M a year. This is and will continue to be a great investment.